+

WO2011067348A3 - Sels d'inhibiteurs de mek et leurs solvates - Google Patents

Sels d'inhibiteurs de mek et leurs solvates Download PDF

Info

Publication number
WO2011067348A3
WO2011067348A3 PCT/EP2010/068763 EP2010068763W WO2011067348A3 WO 2011067348 A3 WO2011067348 A3 WO 2011067348A3 EP 2010068763 W EP2010068763 W EP 2010068763W WO 2011067348 A3 WO2011067348 A3 WO 2011067348A3
Authority
WO
WIPO (PCT)
Prior art keywords
solvates
mek inhibitor
indolizine
phenylamino
tetrahydro
Prior art date
Application number
PCT/EP2010/068763
Other languages
English (en)
Other versions
WO2011067348A2 (fr
Inventor
Liladhar Murlidhar Waykole
Piotr H. Karpinski
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of WO2011067348A2 publication Critical patent/WO2011067348A2/fr
Publication of WO2011067348A3 publication Critical patent/WO2011067348A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention a pour objet des formes de sels de sodium du (2-hydroxyéthoxy)-amide de l'acide 7-(4-bromo-2-fluoro-phénylamino)-6-méthyl-5-oxo-1,3,5-tétrahydro- indolizine-8-carboxylique et du cyclopropylméthoxy-amide de l'acide 7-(4-bromo-2-fluoro-phénylamino)-5-oxo-1,2,3,5-tétrahydro-indolizine-8- carboxylique et leurs solvates et polymorphes correspondants, qui sont utiles dans le traitement d'une maladie, d'un trouble ou d'un syndrome associé à l'inhibition de MEK, tel qu'un cancer, chez les mammifères.
PCT/EP2010/068763 2009-12-03 2010-12-02 Sels d'inhibiteurs de mek et leurs solvates WO2011067348A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26641009P 2009-12-03 2009-12-03
US61/266,410 2009-12-03
US26684209P 2009-12-04 2009-12-04
US61/266,842 2009-12-04

Publications (2)

Publication Number Publication Date
WO2011067348A2 WO2011067348A2 (fr) 2011-06-09
WO2011067348A3 true WO2011067348A3 (fr) 2011-08-04

Family

ID=44009944

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/068763 WO2011067348A2 (fr) 2009-12-03 2010-12-02 Sels d'inhibiteurs de mek et leurs solvates

Country Status (1)

Country Link
WO (1) WO2011067348A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109142A1 (fr) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Inhibition de la voie des mapk/erk et pdk combinée dans des cas de néoplasie
WO2015041533A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut Association de rock et de la voie mapk
WO2015041534A1 (fr) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk en combinaison avec raf/erk/mek
US20170027940A1 (en) 2014-04-10 2017-02-02 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (fr) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions pour le traitement du cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275606A1 (en) * 2008-04-21 2009-11-05 Novartis Ag Heterocyclic Compounds as MEK Inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666901B2 (en) 2004-10-13 2010-02-23 Wyeth Analogs of 17-hydroxywortmannin as PI3K inhibitors
CA2599320A1 (fr) 2005-02-25 2006-08-31 Kudos Pharmaceuticals Limited Composes
EP1871377A1 (fr) 2005-02-25 2008-01-02 Kudos Pharmaceuticals Ltd Derives de 2 , 4-diamino-pyridopyrimidine et leur utilisation comme inhibiteurs mtor
CA2628920C (fr) 2005-11-22 2015-12-29 Kudos Pharmaceuticals Limited Derives de pyrido-, pyrazo- et pyrimido-pyrimidine en tant qu'inhibiteurs de mtor
BRPI0706395A2 (pt) 2006-01-11 2011-03-22 Astrazeneca Ab composto, uso do mesmo, métodos para produzir um efeito anti-proliferativo em um animal de sangue quente e para tratar doença, composição farmacêutica, e, processo para preparar um composto
ES2648388T3 (es) 2006-08-23 2018-01-02 Kudos Pharmaceuticals Limited Derivados de 2-metilmorfolin pirido-, pirazo- y pirimido-pirimidina como inhibidores de mTOR
EP2227469B9 (fr) 2007-11-12 2014-09-10 Takeda Pharmaceutical Company Limited Inhibiteurs de la mapk/erk kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090275606A1 (en) * 2008-04-21 2009-11-05 Novartis Ag Heterocyclic Compounds as MEK Inhibitors

Also Published As

Publication number Publication date
WO2011067348A2 (fr) 2011-06-09

Similar Documents

Publication Publication Date Title
HK1225733B (zh) 用於治療疾病的雙重抑制劑
BRPI1013426A2 (pt) organismos para produção de 1,3-butanodiol
MX2009013990A (es) Metodos para tratar enfermedades y trastornos mediados por serotonina.
MX297669B (es) Produccion de di-esteres de acido tereftalico.
SMT201700529T1 (it) Metodi per un'aumentata produzione di proteine
PL2324831T3 (pl) Terapia pirfenidonem z wykluczeniem fluwoksaminy
FI20095836L (fi) Probioottinen valmiste koirien maha- ja suolistohäiriöiden ennaltaehkäisyyn tai hoitoon
BRPI1008021A2 (pt) Método para fabricação de 2,6-dioxabiciclo-(3.3.0)-octano-4,8-diona
IL208350A0 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease
AP2012006227A0 (en) Derivatives of purine or deazapurine useful for the treatment of inter, alia viral, infections.
WO2012025944A3 (fr) Sitagliptine, sels et polymorphes de celle-ci
PH12012500278A1 (en) Substituted xanthine derivatives
IT1394503B1 (it) Sali di 6'-sialillattosio e processo per la loro sintesi e per la sintesi di altri alfa-sialiloligosaccaridi.
HRP20130476T1 (hr) Derivati imidazopiridina koji inhibiraju sekreciju želuäśane kiseline
IN2012DN01642A (fr)
MX2012005225A (es) Compuestos y composiciones de purina n-7 sustituida y pirazolopirimidina, y metodos de uso.
WO2011067348A3 (fr) Sels d'inhibiteurs de mek et leurs solvates
WO2010046926A3 (fr) Nouveaux analogues de stilbène
EP2243486A4 (fr) Promoteur de la production d'adrénomédulline
WO2011067356A3 (fr) Polymorphes d'un inhibiteur de mek
FR2947265B1 (fr) Procede de preparation d'alkylalcanolamines
FR2941435B3 (fr) Structure flottante, bateau ou simulaire
WO2011027359A3 (fr) Nouveau procédé de préparation de 4-hydroxy atomoxétine
IT1398835B1 (it) Centro di lavoro per la realizzazione di parti di serramenti lignei.
WO2010109185A3 (fr) Procédé de préparation de la doxazosine et de ses sels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10784318

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10784318

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载